EAGLE PHARMACEUTICALS, INC.
EGRX$413M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWOODCLIFF LAKE
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Feb 10, 2026
2dData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
CAL02 Phase 2 Results Expected
Feb 10, 2026CAL02276
Primary completion for CAL02 trial (NCT05776004) in Pneumonia, Bacterial
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
Ryanodex and Standard of Care
Exertional Heat Stroke
CAL02
Pneumonia, Bacterial
Dantrolene sodium for injectable suspension
Heat Stroke
SeeMore(TM)
Myocardial Infarction
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Ryanodex and Standard of Care | Phase 3 | Exertional Heat Stroke | - |
CAL02 | Phase 2 | Pneumonia, Bacterial | - |
Dantrolene sodium for injectable suspension | Phase 2 | Heat Stroke | - |
SeeMore(TM) | Phase 2 | Myocardial Infarction | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
EGRX News